Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ablation of Intestinal Metaplasia Containing Dysplasia (AIM Dysplasia Trial) A Multi-center, Randomized, Sham-Controlled Trial: Protocol Amendment to Extend Follow-up to 5 Years

NCT00282672 is registered in ClinicalTrials.gov with Medtronic - MITG as lead sponsor.

NCT NCT00282672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00282672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ablation of Intestinal Metaplasia Containing Dysplasia (AIM Dysplasia Trial) A Multi-center, Randomized, Sham-Controlled Trial: Protocol Amendment to Extend Follow-up to 5 Years
Lead sponsor
Medtronic - MITG
Phase
Not applicable
Overall status
Completed
Start date
February 28, 2006
Completion date
August 31, 2014
Enrollment
127 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

barrett esophagus